News
The FDA accepted a resubmitted new drug application for reproxalap, a first-in-class investigational topical therapy for dry ...
InvestorsHub on MSN13h
Clearside Biomedical Receives Canadian Approval for XIPERE® to Treat Uveitic Macular Edema via Suprachoroidal Delivery
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical firm pioneering therapies delivered through the suprachoroidal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback